DKK 5.6
(-4.44%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 21.22 Million DKK | 36.28% |
2022 | 15.57 Million DKK | 40.31% |
2021 | 11.1 Million DKK | 81.38% |
2020 | 6.11 Million DKK | 55.66% |
2019 | 3.93 Million DKK | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 4.02 Million DKK | 0.0% |
2024 Q1 | 4.02 Million DKK | -36.4% |
2023 Q4 | 6.64 Million DKK | 100.0% |
2023 Q1 | 7.21 Million DKK | -24.06% |
2023 FY | - DKK | 36.28% |
2023 Q3 | 3.32 Million DKK | -76.97% |
2023 Q2 | 14.43 Million DKK | 100.0% |
2022 Q4 | 9.5 Million DKK | 100.0% |
2022 FY | - DKK | 40.31% |
2022 Q3 | 4.75 Million DKK | -18.74% |
2022 Q2 | 5.84 Million DKK | 100.0% |
2022 Q1 | 2.92 Million DKK | 64.24% |
2021 Q1 | 3.66 Million DKK | 0.0% |
2021 FY | - DKK | 81.38% |
2021 Q4 | 1.78 Million DKK | 0.0% |
2021 Q3 | 1.78 Million DKK | -51.47% |
2021 Q2 | 3.66 Million DKK | 0.0% |
2020 FY | - DKK | 55.66% |
2019 FY | - DKK | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Ambu A/S | 691 Million DKK | 96.928% |
ChemoMetec A/S | 193.97 Million DKK | 89.058% |
Demant A/S | 5.21 Billion DKK | 99.593% |
GN Store Nord A/S | 2.31 Billion DKK | 99.082% |
ViroGates A/S | -12.48 Million DKK | 270.062% |